Stahl’s Essential Psychopharmacology
5th Edition Test Bank: Chapters 1-13
with 200+questions Complete Study
Guide (new updated)
Question 1: Chemical Neurotransmission
A patient is prescribed a medication that targets volume neurotransmission. Which of the following best
describes this process?
A. Communication between two neurons via a tight gap junction.
B. The rapid reuptake of serotonin by the presynaptic transporter.
C. Neurotransmitters diffusing to receptors outside of the immediate synapse.
D. The conversion of an electrical impulse into a chemical signal at the trigger zone.
Answer: C. Neurotransmitters diffusing to receptors outside of the immediate synapse.
Rationale: In "Stahl's Essential Psychopharmacology," volume neurotransmission (or non-synaptic
diffusion neurotransmission) occurs when neurotransmitters spill over from the synapse and diffuse to
distant receptors that are not part of the traditional "point-to-point" synapse. This is common in the
dopamine system of the prefrontal cortex and in the action of gases like nitric oxide.
Question 2: Signal Transduction
What is the final common pathway or "ultimate goal" of signal transduction cascades within a neuron?
A. The opening of ligand-gated ion channels.
B. The activation of third-messenger phosphoproteins.
C. Changing the expression of genes via transcription factors.
D. The immediate release of neurotransmitters from vesicles.
Answer: C. Changing the expression of genes via transcription factors.
,Rationale: Stahl describes signal transduction as a "molecular pony express." While it involves many
steps (G-proteins, second messengers, etc.), the ultimate functional goal is to reach the nucleus and
activate transcription factors like CREB, which change gene expression to produce long-term changes
in neuronal function and synaptogenesis.
Question 3: G-Protein-Linked Receptors
Which of the following is a characteristic of G-protein-linked receptors?
A. They contain four transmembrane regions.
B. They are responsible for very fast (millisecond) neurotransmission.
C. They possess seven transmembrane-spanning segments.
D. They always act to inhibit the cell’s firing rate.
Answer: C. They possess seven transmembrane-spanning segments.
Rationale: G-protein-linked receptors, also known as metabotropic receptors, are characterized by
seven transmembrane regions. Unlike ionotropic receptors (which have 4-5 regions and act quickly),
G-protein-linked receptors act more slowly and involve complex intracellular signaling.
Question 4: Schizophrenia and Dopamine
Hyperactivity in which dopamine pathway is primarily associated with the "positive" symptoms of
schizophrenia, such as hallucinations and delusions?
A. Mesocortical pathway.
B. Mesolimbic pathway.
C. Nigrostriatal pathway.
D. Tuberoinfundibular pathway.
Answer: B. Mesolimbic pathway.
Rationale: The dopamine hypothesis of schizophrenia posits that overactivity specifically in the
mesolimbic dopamine pathway (projecting from the VTA to the nucleus accumbens) mediates positive
symptoms. Antipsychotics work by blocking D2 receptors in this specific area to reduce these
symptoms.
Question 5: Antipsychotic Side Effects
Blockade of dopamine D2 receptors in the nigrostriatal pathway is most likely to result in which of the
following?
A. Reduced hallucinations.
B. Increased prolactin levels.
C. Improved cognitive focus.
D. Extrapyramidal symptoms (EPS).
Answer: D. Extrapyramidal symptoms (EPS).
,Rationale: The nigrostriatal pathway controls motor movement. When antipsychotics block D2
receptors in this pathway, it mimics the dopamine deficiency seen in Parkinson’s disease, leading to
motor side effects known as extrapyramidal symptoms, including tremors and rigidity.
Question 6: Atypical Antipsychotics
The "atypical" clinical profile of second-generation antipsychotics is largely attributed to which
pharmacological property?
A. Pure D2 receptor antagonism.
B. 5-HT2A receptor antagonism combined with D2 antagonism.
C. Selective inhibition of the norepinephrine transporter.
D. Rapid dissociation from the 5-HT1A receptor.
Answer: B. 5-HT2A receptor antagonism combined with D2 antagonism.
Rationale: The hallmark of atypicality is 5-HT2A antagonism. By blocking 5-HT2A receptors, these
drugs can actually increase dopamine release in the nigrostriatal and mesocortical pathways, which
offsets some of the negative effects of D2 blockade and reduces the risk of EPS.
Question 7: Mood Disorders
According to the monoamine receptor hypothesis, what happens to receptors when there is a chronic
"deficiency" of neurotransmitters?
A. Receptors down-regulate.
B. Receptors remain unchanged.
C. Receptors up-regulate (increase in sensitivity or number).
D. Receptors are immediately destroyed by enzymes.
Answer: C. Receptors up-regulate (increase in sensitivity or number).
Rationale: The hypothesis suggests that in depression, a low level of monoamines causes the
postsynaptic receptors to "up-regulate" or increase in number to try and capture any available signal.
Antidepressants work by increasing neurotransmitters, which eventually causes these receptors to
down-regulate back to a normal state.
Question 8: SSRI Mechanism
When starting an SSRI, why does it typically take 2-4 weeks for a patient to feel a therapeutic effect?
A. The drug takes that long to cross the blood-brain barrier.
B. It takes time for the drug to reach steady-state plasma levels.
C. It requires time for the down-regulation of somatodendritic 5-HT1A autoreceptors.
D. The liver must metabolize the drug into an active form first.
Answer: C. It requires time for the down-regulation of somatodendritic 5-HT1A autoreceptors.
Rationale: Initially, SSRIs increase serotonin at the cell body (somatodendritic area). This activates 5-
HT1A autoreceptors, which actually shut down further serotonin release. It takes weeks for these
, autoreceptors to down-regulate (become desensitized), which finally allows the neuron to fire and
release serotonin at the axon terminal.
Question 9: GABA and Anxiety
Benzodiazepines are classified as which type of modulator at the GABA-A receptor?
A. Competitive agonist.
B. Irreversible antagonist.
C. Positive Allosteric Modulator (PAM).
D. Negative Allosteric Modulator (NAM).
Answer: C. Positive Allosteric Modulator (PAM).
Rationale: Benzodiazepines do not bind to the same site as GABA; they bind to a different (allosteric)
site. When they bind, they enhance the effect of GABA by increasing the frequency of the chloride
channel opening, thereby making the inhibitory effect "more positive."
Question 10: Glutamate and Ketamine
Ketamine acts as an antidepressant by targeting which of the following?
A. Serotonin transporters.
B. NMDA receptor antagonism.
C. GABA-A receptor agonism.
D. Monoamine oxidase inhibition.
Answer: B. NMDA receptor antagonism.
Rationale: Ketamine is a non-competitive NMDA receptor antagonist. By blocking NMDA receptors on
GABAergic interneurons, it causes a "burst" of glutamate release that leads to rapid synaptogenesis,
explaining its rapid-acting antidepressant effects compared to traditional monoamine-based drugs.
Question 11: Antipsychotic Mechanisms
Rapid dissociation from the dopamine D2 receptor is a characteristic specifically proposed for which of
the following?
A. Haloperidol
B. Quetiapine
C. Chlorpromazine
D. Fluphenazine
Answer: B. Quetiapine
Rationale: Quetiapine and Clozapine are known for their "fast-off" kinetics. According to the "hit-and-
run" hypothesis in Stahl's, these drugs bind loosely to D2 receptors and dissociate quickly, which
provides therapeutic effects while minimizing the risk of extrapyramidal symptoms (EPS) and
hyperprolactinemia.
5th Edition Test Bank: Chapters 1-13
with 200+questions Complete Study
Guide (new updated)
Question 1: Chemical Neurotransmission
A patient is prescribed a medication that targets volume neurotransmission. Which of the following best
describes this process?
A. Communication between two neurons via a tight gap junction.
B. The rapid reuptake of serotonin by the presynaptic transporter.
C. Neurotransmitters diffusing to receptors outside of the immediate synapse.
D. The conversion of an electrical impulse into a chemical signal at the trigger zone.
Answer: C. Neurotransmitters diffusing to receptors outside of the immediate synapse.
Rationale: In "Stahl's Essential Psychopharmacology," volume neurotransmission (or non-synaptic
diffusion neurotransmission) occurs when neurotransmitters spill over from the synapse and diffuse to
distant receptors that are not part of the traditional "point-to-point" synapse. This is common in the
dopamine system of the prefrontal cortex and in the action of gases like nitric oxide.
Question 2: Signal Transduction
What is the final common pathway or "ultimate goal" of signal transduction cascades within a neuron?
A. The opening of ligand-gated ion channels.
B. The activation of third-messenger phosphoproteins.
C. Changing the expression of genes via transcription factors.
D. The immediate release of neurotransmitters from vesicles.
Answer: C. Changing the expression of genes via transcription factors.
,Rationale: Stahl describes signal transduction as a "molecular pony express." While it involves many
steps (G-proteins, second messengers, etc.), the ultimate functional goal is to reach the nucleus and
activate transcription factors like CREB, which change gene expression to produce long-term changes
in neuronal function and synaptogenesis.
Question 3: G-Protein-Linked Receptors
Which of the following is a characteristic of G-protein-linked receptors?
A. They contain four transmembrane regions.
B. They are responsible for very fast (millisecond) neurotransmission.
C. They possess seven transmembrane-spanning segments.
D. They always act to inhibit the cell’s firing rate.
Answer: C. They possess seven transmembrane-spanning segments.
Rationale: G-protein-linked receptors, also known as metabotropic receptors, are characterized by
seven transmembrane regions. Unlike ionotropic receptors (which have 4-5 regions and act quickly),
G-protein-linked receptors act more slowly and involve complex intracellular signaling.
Question 4: Schizophrenia and Dopamine
Hyperactivity in which dopamine pathway is primarily associated with the "positive" symptoms of
schizophrenia, such as hallucinations and delusions?
A. Mesocortical pathway.
B. Mesolimbic pathway.
C. Nigrostriatal pathway.
D. Tuberoinfundibular pathway.
Answer: B. Mesolimbic pathway.
Rationale: The dopamine hypothesis of schizophrenia posits that overactivity specifically in the
mesolimbic dopamine pathway (projecting from the VTA to the nucleus accumbens) mediates positive
symptoms. Antipsychotics work by blocking D2 receptors in this specific area to reduce these
symptoms.
Question 5: Antipsychotic Side Effects
Blockade of dopamine D2 receptors in the nigrostriatal pathway is most likely to result in which of the
following?
A. Reduced hallucinations.
B. Increased prolactin levels.
C. Improved cognitive focus.
D. Extrapyramidal symptoms (EPS).
Answer: D. Extrapyramidal symptoms (EPS).
,Rationale: The nigrostriatal pathway controls motor movement. When antipsychotics block D2
receptors in this pathway, it mimics the dopamine deficiency seen in Parkinson’s disease, leading to
motor side effects known as extrapyramidal symptoms, including tremors and rigidity.
Question 6: Atypical Antipsychotics
The "atypical" clinical profile of second-generation antipsychotics is largely attributed to which
pharmacological property?
A. Pure D2 receptor antagonism.
B. 5-HT2A receptor antagonism combined with D2 antagonism.
C. Selective inhibition of the norepinephrine transporter.
D. Rapid dissociation from the 5-HT1A receptor.
Answer: B. 5-HT2A receptor antagonism combined with D2 antagonism.
Rationale: The hallmark of atypicality is 5-HT2A antagonism. By blocking 5-HT2A receptors, these
drugs can actually increase dopamine release in the nigrostriatal and mesocortical pathways, which
offsets some of the negative effects of D2 blockade and reduces the risk of EPS.
Question 7: Mood Disorders
According to the monoamine receptor hypothesis, what happens to receptors when there is a chronic
"deficiency" of neurotransmitters?
A. Receptors down-regulate.
B. Receptors remain unchanged.
C. Receptors up-regulate (increase in sensitivity or number).
D. Receptors are immediately destroyed by enzymes.
Answer: C. Receptors up-regulate (increase in sensitivity or number).
Rationale: The hypothesis suggests that in depression, a low level of monoamines causes the
postsynaptic receptors to "up-regulate" or increase in number to try and capture any available signal.
Antidepressants work by increasing neurotransmitters, which eventually causes these receptors to
down-regulate back to a normal state.
Question 8: SSRI Mechanism
When starting an SSRI, why does it typically take 2-4 weeks for a patient to feel a therapeutic effect?
A. The drug takes that long to cross the blood-brain barrier.
B. It takes time for the drug to reach steady-state plasma levels.
C. It requires time for the down-regulation of somatodendritic 5-HT1A autoreceptors.
D. The liver must metabolize the drug into an active form first.
Answer: C. It requires time for the down-regulation of somatodendritic 5-HT1A autoreceptors.
Rationale: Initially, SSRIs increase serotonin at the cell body (somatodendritic area). This activates 5-
HT1A autoreceptors, which actually shut down further serotonin release. It takes weeks for these
, autoreceptors to down-regulate (become desensitized), which finally allows the neuron to fire and
release serotonin at the axon terminal.
Question 9: GABA and Anxiety
Benzodiazepines are classified as which type of modulator at the GABA-A receptor?
A. Competitive agonist.
B. Irreversible antagonist.
C. Positive Allosteric Modulator (PAM).
D. Negative Allosteric Modulator (NAM).
Answer: C. Positive Allosteric Modulator (PAM).
Rationale: Benzodiazepines do not bind to the same site as GABA; they bind to a different (allosteric)
site. When they bind, they enhance the effect of GABA by increasing the frequency of the chloride
channel opening, thereby making the inhibitory effect "more positive."
Question 10: Glutamate and Ketamine
Ketamine acts as an antidepressant by targeting which of the following?
A. Serotonin transporters.
B. NMDA receptor antagonism.
C. GABA-A receptor agonism.
D. Monoamine oxidase inhibition.
Answer: B. NMDA receptor antagonism.
Rationale: Ketamine is a non-competitive NMDA receptor antagonist. By blocking NMDA receptors on
GABAergic interneurons, it causes a "burst" of glutamate release that leads to rapid synaptogenesis,
explaining its rapid-acting antidepressant effects compared to traditional monoamine-based drugs.
Question 11: Antipsychotic Mechanisms
Rapid dissociation from the dopamine D2 receptor is a characteristic specifically proposed for which of
the following?
A. Haloperidol
B. Quetiapine
C. Chlorpromazine
D. Fluphenazine
Answer: B. Quetiapine
Rationale: Quetiapine and Clozapine are known for their "fast-off" kinetics. According to the "hit-and-
run" hypothesis in Stahl's, these drugs bind loosely to D2 receptors and dissociate quickly, which
provides therapeutic effects while minimizing the risk of extrapyramidal symptoms (EPS) and
hyperprolactinemia.
